- Home
- ALGS vs PYPD Comparison
ALGS vs PYPD Comparison
Compare ALGS & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- PYPD
- Stock Information
- Founded
- ALGS 2018
- PYPD 2008
- Country
- ALGS United States
- PYPD Israel
- Employees
- ALGS 70
- PYPD N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- ALGS Health Care
- PYPD Health Care
- Exchange
- ALGS Nasdaq
- PYPD Nasdaq
- Market Cap
- ALGS 27.9M
- PYPD 25.0M
- IPO Year
- ALGS 2020
- PYPD 2020
- Fundamental
- Price
- ALGS $5.36
- PYPD $2.75
- Analyst Decision
- ALGS Strong Buy
- PYPD Strong Buy
- Analyst Count
- ALGS 1
- PYPD 2
- Target Price
- ALGS $70.00
- PYPD $10.50
- AVG Volume (30 Days)
- ALGS 184.5K
- PYPD 10.5K
- Earning Date
- ALGS 05-06-2025
- PYPD 05-07-2025
- Dividend Yield
- ALGS N/A
- PYPD N/A
- EPS Growth
- ALGS N/A
- PYPD N/A
- EPS
- ALGS N/A
- PYPD N/A
- Revenue
- ALGS $3,945,000.00
- PYPD N/A
- Revenue This Year
- ALGS $580.86
- PYPD N/A
- Revenue Next Year
- ALGS N/A
- PYPD N/A
- P/E Ratio
- ALGS N/A
- PYPD N/A
- Revenue Growth
- ALGS N/A
- PYPD N/A
- 52 Week Low
- ALGS $3.76
- PYPD $2.30
- 52 Week High
- ALGS $46.80
- PYPD $5.09
- Technical
- Relative Strength Index (RSI)
- ALGS 33.94
- PYPD 52.19
- Support Level
- ALGS $4.33
- PYPD $2.65
- Resistance Level
- ALGS $5.67
- PYPD $2.76
- Average True Range (ATR)
- ALGS 0.78
- PYPD 0.11
- MACD
- ALGS 0.43
- PYPD 0.03
- Stochastic Oscillator
- ALGS 49.61
- PYPD 93.75
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.